Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Krazati
Research
Researchers find 'highly synergistic' pancreatic cancer combo
A new study has found one potentially beneficial combo for pancreatic cancer: Mirati's KRAS inhibitor Krazati and Boehringer Ingelheim’s Gilotrif.
Helen Floersh
Jun 30, 2023 12:57pm
Mirati's wait for next lung cancer med ends in phase 3 failure
May 24, 2023 4:00pm
Mirati eyes 'highest opportunity for capital' in pipeline build
Jan 9, 2023 1:37pm
Mirati pressures Amgen with Keytruda combo show in lung cancer
Dec 6, 2022 9:15am
Mirati KRAS data are 'identical' to Amgen's, researcher, CEO say
Jun 6, 2022 10:00am
Mirati cedes to Amgen's Lumakras on durability in KRAS battle
May 27, 2022 10:18am
